COVID-19
Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.
As the COVID-19 pandemic hit a grim milestone, marking more U.S. deaths than were reported in the 1918–19 Spanish flu pandemic, research and breakthroughs continue.
On the tailcoat of Tuesday’s United Nations General Assembly, President Biden is hosting a virtual COVID-19 summit Wednesday, calling for the end of the pandemic globally.
In September 20, 2021, the United States marked a grisly milestone, recording more American deaths from COVID-19 than died from the 1918-1919 Spanish flu pandemic.
The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.
The vote to offer a booster to those 65 and older, as well as immunocompromised individuals at high risk of developing severe COVID-19, was a unanimous “yea” at 18-0.
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.”
COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
The COVID-19 pandemic has changed science journalism. Semantics aside, though, science and health care have taken a new position in the hierarchy of top news priorities.
PRESS RELEASES